新诊断2型糖尿病初始联合与阶梯治疗的β细胞恢复模式:TRIPLE-AXEL事后分析
TRIPLE-AXEL试验事后分析纳入75例完成104周治疗的新诊断2型糖尿病患者,比较初始三联联合治疗(TCT)与阶梯添加治疗(SAT)对β细胞功能的影响。两组HbA1c均下降约2.7%,处置指数(DI)均显著升高且组间无显著差异;TCT组无低血糖发生,SAT组低血糖发生率为23.7%。
要点
- 两种早期治疗策略均改善β细胞功能,组间无显著差异。
- TCT组无低血糖发生,SAT组低血糖发生率为23.7%。
- HbA1c降幅越大与第104周DI越高相关。
核心结论
- 在新诊断T2DM中,初始三联联合治疗与阶梯添加治疗均改善β细胞功能,组间无显著差异。
- TCT实现上述改善且无低血糖发生,但基于治疗中评估不能得出生理等效结论。
研究设计与样本
- TRIPLE-AXEL试验的事后分析,纳入75例完成104周治疗且基线和第104周行75-g口服葡萄糖耐量试验的初治参与者。
- 参与者随机接受初始三联联合治疗(TCT:二甲双胍、达格列净和沙格列汀)或阶梯添加治疗(SAT:二甲双胍后加格列美脲和西格列汀)。
- 采用胰岛素生成指数(IGI)、Matsuda胰岛素敏感性指数(ISI)和处置指数(DI)分别评估胰岛素分泌、胰岛素敏感性和β细胞代偿功能。
主要发现
- 两组HbA1c在104周内均下降约2.7%。
- TCT和SAT的DI均显著升高,基线校正后变化组间差异无统计学意义(差异−0.09 [95%CI −0.44至0.27];p=0.63)。
- IGI和ISI的基线校正后变化组间亦无显著差异(p=0.35和p=0.85),但ISI的组内升高仅在TCT组显著。
- 多变量模型中,HbA1c降幅越大与第104周DI越高相关。
- 低血糖在TCT组无发生,在SAT组发生率为23.7%。
临床怎么用
- 新诊断T2DM可考虑早期联合治疗以改善β细胞功能,但需结合低血糖风险个体化选择。
- TCT方案在本分析中未发生低血糖,可作为低血糖高风险患者的参考选项。
局限性
- 为事后分析,样本量较小(75例)。
- β细胞功能评估在治疗中进行,不能得出生理等效结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Early intensive therapy may preserve β-cell function in newly diagnosed Type 2 diabetes mellitus (T2DM), but whether different early treatment strategies produce distinct patterns of β-cell functional recovery remains unclear. Methods This post hoc analysis of the TRIPLE-AXEL trial included 75 drug-naïve participants who completed 104 weeks of treatment and underwent 75-g oral glucose tolerance tests at baseline and Week 104. Participants were randomized to initial triple combination therapy (TCT; metformin, dapagliflozin and saxagliptin) or stepwise add-on therapy (SAT; metformin followed by glimepiride and sitagliptin). Insulin secretion, insulin sensitivity and β-cell compensatory function were assessed using the insulinogenic index (IGI), Matsuda insulin sensitivity index (ISI) and disposition index (DI), respectively. Results HbA1c decreased by approximately 2.7% over 104 weeks in both groups. DI increased significantly in both TCT and SAT, with no significant between-group difference in the baseline-adjusted change (difference, −0.09 [95% CI, −0.44 to 0.27]; p = 0.63). Baseline-adjusted changes in IGI and ISI also did not differ significantly between groups (p = 0.35 and p = 0.85, respectively), although the within-group increase in ISI was significant only in the TCT group. In multivariable models, greater HbA1c reduction was associated with higher DI at Week 104. Hypoglycaemia occurred in none of the participants in the TCT group and in 23.7% of those in the SAT group. Conclusions In newly diagnosed T2DM, both treatment strategies improved β-cell function without significant between-group differences. TCT achieved this without hypoglycaemia; however, given the on-treatment assessment, physiological equivalence cannot be concluded. Trial Registration ClinicalTrials.gov identifier: NCT02946632
引用
- Diabetes, Obesity and Metabolism:β‐Cell Recovery Patterns With Initial Combination Versus Stepwise Therapy in Newly Diagnosed Type 2 Diabetes: TRIPLE‐AXEL Post Hoc Analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。